Plus, trastuzumab, an anti‐HER2 agent, facilitates the expression of HER3 in breast cancer cells, and its overexpression can also activate PI3K/AKT pathway, resulting in resistance to anti‐HER2 therapies [5]. This evidence concerns the gene AKT1 and breast cancer.